We found that treatment with either the ERK or IGF1R inhibitors was able to restore sensitivity to vermurafenib in both HAT1-knockdown and HAT1-KO BRAFi-resistant melanoma cells, in both the soft-agar assay (Fig. 5d–g) and in the clonogenic long-term survival assay (Fig. 6c–f). Here, IGF1R is linked to melanoma.